The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients

Transplant Immunology

Volumn 26, Issue 4, 2012, Pages 186-190

  Kho, M M L ^a   Bouvy, A P ^a   Cadogan, M ^a   Kraaijeveld, R ^a   Baan, C C ^a   Weimar, W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Kidney transplantation; Lymphocyte subsets; Monitoring; R ATG; Thymoglobulin

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL COUNT; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE;

ADULT; AGED; ANTILYMPHOCYTE SERUM; B-LYMPHOCYTES; CELL COUNT; DRUG DOSAGE CALCULATIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84860465184     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.02.003     Document Type: Article

References (33)

1. Monaco A.P., Wood M.L., Russel P.S. Some effects of purified heterologous antihuman lymphocyte serum in man. Transplantation 1967, 5(4):1106-1114.
2. Kashiwagi N., Brantigan C.O., Brettschneider L., Groth C.G., Starzl T.E. Clinical reactions and serologic changes after the administration of heterologous antilymphocyte globulin to human recipients of renal homografts. Ann Intern Med 1968, 68(2):275-286.
3. Padiyar A., Augustine J.J., Hricik D.E. Induction antibody therapy in kidney transplantation. Am J Kidney Dis 2009, 54(5):935-944.
4. Axelrod D.A., McCullough K.P., Brewer E.D., Becker B.N., Segev D.L., Rao P.S. Kidney and pancreas transplantation in the United States, 1999-2008: the changing face of living donation. Am J Transplant 2010, 10(part 2):987-1002.
5. Opelz G., Naujokat C., Daniel V., Terness P., Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006, 82(9):1227-1233.
6. Thibaudin D., Alamartine E., Mariat C., Absi L., Berthoux F. Long-term kinetic of T-lymphocyte subsets in kidney transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies. Transplantation 2005, 80(10):1514-1517.
7. Meier-Kriesche H.U., Arndorfer J.A., Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002, 13:769-772.
8. Szczech L.A., Berlin J.A., Aradhy S., Grossman R.A., Feldman H.I. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997, 9:1771-1777.
9. Webster A.C., Ruster L.P., McGee R., Matheson S.L., Higgins G.Y., Willis N.S., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010, 1:CD003897.
10. Ducloux D., Courivaud C., Bamoulid J., Vivet B., Chabroux A., Deschamps M., et al. Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. J Am Soc Nephrol 2010, 21(5):868-875.
11. Ducloux D., Bamoulid J., Courivaud C., Gaugler B., Rebibou J.M., Ferrand C., et al. Thymic function, anti-thymocytes globulins, and cancer after renal transplantation. Transpl Immunol 2011, 25:56-60.
12. Peddi V.R., Bryant M., Roy-Chaudhury P., Woodle E.S., First M.R. Safety, efficacy and cost-analysis of Thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002, 73(9):1514-1518.
13. Wong W., Agrawal N., Pascual M., Anderson D.C., Hirsch H.H., Fujimoto K., et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006, 19:629-635.
14. Klem P., Cooper J.E., Weiss A.S., Gralla J., Owen P., Chan L., et al. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. Transplantation 2009, 88(7):891-896.
15. Pankewycz O., Leca N., Kohli R., Wallace P.K., Said M., Feng L., et al. Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression. Transplant Proc 2011, 43:462-465.
16. Solez K., Colvin R.B., Racusen L.C., Haas M., Sis B., Mengel M., et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008, 8:753-760.
17. Guttmann R.D., Caudrelier P., Alberici G., Touraine J.L. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997, 29(7A):24S-26S.
18. Brennan D.C., Flavin K., Lowell J.A., Howard T.K., Shenoy S., Burgess S., et al. Leukocyte response to Thymoglobulin or Atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplant Proc 1999, 31(Suppl. 3B):16S-18S.
19. Agha I.A., Rueda J., Alvarez A., Singer G., Miller B., Flavin K., et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002, 73(3):473-475.
20. Gurkan S., Luan Y., Dhillon N., Allam S.R., Montagued T., Bromberga J.S., et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010, 10:2132-2141.
21. Weimer R., Staak A., Süsal C., Streller S., Yildiz S., Pelzl S., et al. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int 2005, 18:226-236.
22. Muller T., Grebe S., Neumann M.C., Heymanns J., Radsak K., Sprenger H., et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997, 64(10):1432-1437.
23. Vacher-Coponat H., Brunet C., Moal V., Loundou A., Bonnet E., Lyonnet L., et al. Tacrolimus/Mycophenolate Mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to Cyclosporine/Azathioprine. Transplantation 2006, 82(4):558-566.
24. Hadaya K., Avila Y., Valloton L., de Rham C., Bandelier C., Ferrari-Lacraz S., et al. Natural killer cell receptor-repertoire and functions after induction therapy by polyclonal rabbit anti-thymocyte globulin in unsensitized kidney transplant recipients. Clin Immunol 2010, 137:250-260.
25. Sageshima J., Ciancio G., Guerra G., Gaynor J.J., Cova D., Zarak A., et al. Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation. Transpl Immunol 2011, 25:104-111.
26. Sewgobind V.D.K.D., Kho M.M.L., van der Laan L.J.W., Hendrikx T.K., van Dam T., Tilanus H.W., et al. The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant 2009, 24(5):1635-1644.
27. Girndt M., Sester U., Sester M., Kaul H., Köhler H. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999, 14(12):2807-2810.
28. Betjes M.G., Langerak A.W., van der Spek A., de Wit E.A., Litjens N.H. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int 2011, 80(2):208-217.
29. Yoon J.W., Gollapudi S., Pahl M.V., Vaziri N.D. Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 2006, 70:371-376.
30. Vacher-Coponat H., Brunet C., Lyonnet L., Bonnet E., Loundou A., Sampol J., et al. Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients. Nephrol Dial Transplant 2008, 23:1406-1414.
31. Zand M.S., Vo T., Huggins J., Felgar R., Liesveld J., Pellegrin T., et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005, 79(11):1507-1515.
32. Waller E.K., Langston A.A., Lonial S., Cherry J., Somani J., Allen A.J., et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003, 9:460-471.
33. Préville X., Flacher M., LeMauff B., Beauchard S., Davelu P., Tiollier J., et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2011, 71(3):460-468.